Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia

A retrospective case series review was conducted to determine the pre-operative role and safety of pre-operative adjunctive anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab “LUCENTISTM” in patients with diabetic retinopathy requiring vitrectomy. The study involved twenty conse...

Full description

Saved in:
Bibliographic Details
Main Authors: Bastion MLC,, Siti Aishah S,, Aida Zairani MZ,, Barkeh HJ,
Format: Article
Language:English
Published: Penerbit UKM 2010
Online Access:http://journalarticle.ukm.my/2086/1/08MS090_4144.pdf
http://journalarticle.ukm.my/2086/
http://www.ppukm.ukm.my/ukmmcjournal/index.php
Tags: Add Tag
No Tags, Be the first to tag this record!
id my-ukm.journal.2086
record_format eprints
spelling my-ukm.journal.20862016-12-14T06:30:51Z http://journalarticle.ukm.my/2086/ Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia Bastion MLC, Siti Aishah S, Aida Zairani MZ, Barkeh HJ, A retrospective case series review was conducted to determine the pre-operative role and safety of pre-operative adjunctive anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab “LUCENTISTM” in patients with diabetic retinopathy requiring vitrectomy. The study involved twenty consecutive eyes of sixteen patients (age range: 46-72 years; mean 57.5 years) which received intravitreal injection of 0.5 - 1 mg of ranibizumab 3 to 8 days (mean 4.4 days) prior to vitrectomy for diabetic retinopathy. There were no local or systemic post-injection complications. Indications for vitrectomy were retinal detachment (RD) [n=11; 3 combined tractional (TRD) - rhegmatogenous RD (RRD), 8 TRD], TRD with vitreous haemorrhage (VH) (n=3) ,VH (n=8) and vitreomacular traction syndrome (n=1). Inclusion criteria include all consecutive eyes of diabetic patients requiring vitrectomy receiving a first pre-operative injection of anti- VEGF. Pre-operative visual acuity (VA) ranged from 6/36 to light perception. All eyes had minimal to moderate intraoperative bleeding. Post-operative VH in eyes without tamponade or gas tamponade was nil (n=1), mild (n=13) or moderate (n=1). Silicone filled eyes had nil (n=1), moderate (n=3) or severe haemorrhages (n=1). Post-operative VA was unchanged (n=2) (10%), improved (n = 14) (70%) or worsened (n=4). VA was 2/60 or better (n=15) to no light perception (n=1). Two eyes achieved 6/12 or better vision (10%). Ten eyes (50%) had 6/36 or better vision. In conclusion, pre-operative intravitreal ranibizumab is safe and useful in diabetic vitrectomy and appears to help with perioperative bleeding leading to improvement in vision. Penerbit UKM 2010 Article PeerReviewed application/pdf en http://journalarticle.ukm.my/2086/1/08MS090_4144.pdf Bastion MLC, and Siti Aishah S, and Aida Zairani MZ, and Barkeh HJ, (2010) Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia. Medicine & Health, 5 (2). pp. 93-102. ISSN 1823-2140 http://www.ppukm.ukm.my/ukmmcjournal/index.php
institution Universiti Kebangsaan Malaysia
building Perpustakaan Tun Sri Lanang Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Kebangsaan Malaysia
content_source UKM Journal Article Repository
url_provider http://journalarticle.ukm.my/
language English
description A retrospective case series review was conducted to determine the pre-operative role and safety of pre-operative adjunctive anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab “LUCENTISTM” in patients with diabetic retinopathy requiring vitrectomy. The study involved twenty consecutive eyes of sixteen patients (age range: 46-72 years; mean 57.5 years) which received intravitreal injection of 0.5 - 1 mg of ranibizumab 3 to 8 days (mean 4.4 days) prior to vitrectomy for diabetic retinopathy. There were no local or systemic post-injection complications. Indications for vitrectomy were retinal detachment (RD) [n=11; 3 combined tractional (TRD) - rhegmatogenous RD (RRD), 8 TRD], TRD with vitreous haemorrhage (VH) (n=3) ,VH (n=8) and vitreomacular traction syndrome (n=1). Inclusion criteria include all consecutive eyes of diabetic patients requiring vitrectomy receiving a first pre-operative injection of anti- VEGF. Pre-operative visual acuity (VA) ranged from 6/36 to light perception. All eyes had minimal to moderate intraoperative bleeding. Post-operative VH in eyes without tamponade or gas tamponade was nil (n=1), mild (n=13) or moderate (n=1). Silicone filled eyes had nil (n=1), moderate (n=3) or severe haemorrhages (n=1). Post-operative VA was unchanged (n=2) (10%), improved (n = 14) (70%) or worsened (n=4). VA was 2/60 or better (n=15) to no light perception (n=1). Two eyes achieved 6/12 or better vision (10%). Ten eyes (50%) had 6/36 or better vision. In conclusion, pre-operative intravitreal ranibizumab is safe and useful in diabetic vitrectomy and appears to help with perioperative bleeding leading to improvement in vision.
format Article
author Bastion MLC,
Siti Aishah S,
Aida Zairani MZ,
Barkeh HJ,
spellingShingle Bastion MLC,
Siti Aishah S,
Aida Zairani MZ,
Barkeh HJ,
Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia
author_facet Bastion MLC,
Siti Aishah S,
Aida Zairani MZ,
Barkeh HJ,
author_sort Bastion MLC,
title Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia
title_short Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia
title_full Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia
title_fullStr Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia
title_full_unstemmed Retrospective review of the adjunctive use of pre- operative ranibizumab “LUCENTISTM” in the surgical management of diabetic retinopathy in a Tertiary Referral Hospital in Malaysia
title_sort retrospective review of the adjunctive use of pre- operative ranibizumab “lucentistm” in the surgical management of diabetic retinopathy in a tertiary referral hospital in malaysia
publisher Penerbit UKM
publishDate 2010
url http://journalarticle.ukm.my/2086/1/08MS090_4144.pdf
http://journalarticle.ukm.my/2086/
http://www.ppukm.ukm.my/ukmmcjournal/index.php
_version_ 1643735260592078848
score 13.160551